(Total Views: 586)
Posted On: 06/16/2022 6:27:04 PM
Post# of 156250
Re: mightycydy #124888
These are Scott Kelly's last words from conference call:
For HIV patients, they have increased risk of NAFLD and NASH compared to general population. Looking at combo therapy for NASH (could he have meant combination of NASH in HIV patients?) with LL and existing agent.
Market is growing at 58.64% annually. Expected to be $180.9billion by 2028.
... Focus is on Partnerships for immunotherapy combination.
Kelly 22:22, so we are in discussions, we have companies under NDA right now. we are advancing the discussions for multiple different applications for LL. But we will have to comment on that when it is publicly available to everybody at the same time.
For HIV patients, they have increased risk of NAFLD and NASH compared to general population. Looking at combo therapy for NASH (could he have meant combination of NASH in HIV patients?) with LL and existing agent.
Market is growing at 58.64% annually. Expected to be $180.9billion by 2028.
... Focus is on Partnerships for immunotherapy combination.
Kelly 22:22, so we are in discussions, we have companies under NDA right now. we are advancing the discussions for multiple different applications for LL. But we will have to comment on that when it is publicly available to everybody at the same time.
(2)
(0)
